Medical Company Receives Special Notice For Its Neuropathic Treatment

VistaGen Therapeutics Receives Notice of Intention to Grant Patent for AV-101's Neuropathic Pain Treatment.

In a significant development in the medical sector, VistaGen Therapeutics Inc., a late clinical-stage biopharmaceutical company, has received a notice of intention to grant a patent from the European Patent Office (EPO) for their product AV-101. The notice pertains to the use of AV-101 in the treatment of neuropathic pain.

Neuropathic pain, a complex and…